Former investment banker @MerrillLynch. Currently CIO of Cedar Grove Capital Management, a multi-strategy hedge fund.
Jun 1, 2026
•
11 min read
Why the decline in the recent IPO improves the R/R, but still leaves potential issues for investors looking to get involved
May 21, 2026
2 min read
Visualizing the decline in valuations in various restaurant concepts while highlighting which the market still seems to give hope to
May 15, 2026
6 min read
Why a recent post from a fellow portfolio manager got us thinking about the current FOMO environment, and why staying the course "generally" works out in the long term
May 5, 2026
7 min read
Analytical Perspectives on Equity Selection and Market Data.
Apr 19, 2026
12 min read
Why Nektar Therapeutics atopic dermatitis (AtD) drug could be significantly undervalued despite being a potential second-line drug treatment option
Apr 10, 2026
4 min read
Apr 2, 2026
13 min read
Quick update on EVLV and why we think that FY'26 guide hints at a long-term opportunity for price appreciation above $10/share.
Mar 23, 2026
25 min read
Going over Q4'25 earnings for current investors and why they might standout for new investors looking new areas for capital deployment
Mar 17, 2026
A quick walkthrough on the math post-deal break, and could LNSR still be compelling as a standalone company?
Mar 15, 2026
15 min read
What one of the best investors on Wall Street has to say about "risk" and what we can learn from it
Mar 10, 2026
14 min read
What both bulls and bears need to understand is the financial impact of HIMS pivoting hard from the compounded GLP-1 strategy
Mar 6, 2026
27 min read
Taking a look at the recent OFRM IPO, co-founded by actress Jennifer Garner, and why it could be an interesting setup for the newest CPG brand to hit the market
Feb 16, 2026
8 min read
Why this prized restaurant asset could strike up a bidding war amongst bidders looking to shore up their position in the quick service restaurant (QSR) space. Potential return could be in excess of 35%.
Feb 9, 2026
24 min read
Why we think Andrew's push deep into compounding GLP-1 land (Russia) has now reached its peak, and the drop is looking like quite the tumble.
Feb 4, 2026
Our chat on all things telehealth and our views on HIMSwith our medical friend from across the pond
19 min read
Why we think this biotech trade, while popular, has limited downside risk in the event no suitor comes to scoop them up.
Jan 27, 2026
Going over the announced LE joint venture by WHP and how there is still a trade on the table
Jan 20, 2026
5 min read
Why recent amendments to SNAP in 2026 could spell trouble for legacy CPG companies
Jan 11, 2026
Why comparing a side-by-side of just how much the U.S. spends on defense is alarming
Jan 5, 2026
34 min read
Why a more dangerous everyday environment is allowing this stock to take advantage
Dec 30, 2025
Sharing learning lessons from 2025 investments to not repeat them // HIMS, GENK, LQDA, REAL
Dec 22, 2025
What we're looking at ahead of the next year, and why they matter
Dec 9, 2025
21 min read
An update on Owlet (OWLT) after a ~226% run-up
Dec 2, 2025
An open discussion with David Helderman, Director of Investor Relations at WW International (WW)
Nov 19, 2025
Why we think this new IPO is doomed to fail